Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:DYAI NASDAQ:RNTX NASDAQ:THAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.77-5.2%$0.77$0.38▼$115.57$8.94M0.711.56 million shs44,314 shsDYAIDyadic International$0.96-2.3%$0.95$0.71▼$2.20$35.44M0.94125,922 shs58,737 shsRNTXRein Therapeutics$1.37+8.7%$1.31$1.04▼$4.40$29.36M1.1399,163 shs259,222 shsTHARTharimmune$3.99-16.4%$2.44$0.95▼$9.08$27.15M1.5630.90 million shs1.59 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma-5.22%-1.30%+4.53%-5.80%-98.71%DYAIDyadic International-2.28%+5.46%-2.38%-3.34%-24.65%RNTXRein Therapeutics+8.73%+21.24%+16.10%-31.50%+136,999,900.00%THARTharimmune-16.35%-34.05%+227.05%+164.26%+34.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.77-5.2%$0.77$0.38▼$115.57$8.94M0.711.56 million shs44,314 shsDYAIDyadic International$0.96-2.3%$0.95$0.71▼$2.20$35.44M0.94125,922 shs58,737 shsRNTXRein Therapeutics$1.37+8.7%$1.31$1.04▼$4.40$29.36M1.1399,163 shs259,222 shsTHARTharimmune$3.99-16.4%$2.44$0.95▼$9.08$27.15M1.5630.90 million shs1.59 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma-5.22%-1.30%+4.53%-5.80%-98.71%DYAIDyadic International-2.28%+5.46%-2.38%-3.34%-24.65%RNTXRein Therapeutics+8.73%+21.24%+16.10%-31.50%+136,999,900.00%THARTharimmune-16.35%-34.05%+227.05%+164.26%+34.34%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/ADYAIDyadic International$3.49M9.92N/AN/A$0.08 per share11.96RNTXRein TherapeuticsN/AN/A$0.49 per share2.81$0.43 per shareN/ATHARTharimmuneN/AN/AN/AN/A$0.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M-$6.084.27N/AN/AN/AN/A-994.63%N/ADYAIDyadic International-$5.81M-$0.19N/AN/AN/A-134.84%-355.39%-60.66%11/11/2025 (Estimated)RNTXRein Therapeutics-$62.88M-$2.69N/AN/AN/AN/A-141.11%-33.83%N/ATHARTharimmune-$12.20M-$6.10N/A∞N/AN/A-1,239.20%-365.06%N/ALatest AEON, THAR, DYAI, and RNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RNTXRein Therapeutics-$0.22-$0.28-$0.06-$0.28N/AN/A8/14/2025Q2 2025THARTharimmune-$0.58-$0.64-$0.06-$0.64N/AN/A8/13/2025Q2 2025DYAIDyadic International-$0.06-$0.06N/A-$0.06$0.60 million$0.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22DYAIDyadic International5.402.022.02RNTXRein TherapeuticsN/A0.860.86THARTharimmuneN/A1.171.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%DYAIDyadic International27.95%RNTXRein Therapeutics90.89%THARTharimmune1.16%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%DYAIDyadic International29.50%RNTXRein Therapeutics5.10%THARTharimmune10.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.64 million74.37 millionNot OptionableDYAIDyadic International736.19 million25.51 millionOptionableRNTXRein Therapeutics923.31 million22.12 millionN/ATHARTharimmune25.69 million5.12 millionNot OptionableAEON, THAR, DYAI, and RNTX HeadlinesRecent News About These CompaniesTharimmune, Inc. to Present Innovative Research at Upcoming Fall Conferences in 2025September 4 at 8:30 AM | quiverquant.comQBiotech Stocks To Watch Today - August 25thAugust 28, 2025 | americanbankingnews.comTharimmune (THUR) Tumbles 20.7% on $5-Million Share SaleAugust 27, 2025 | insidermonkey.comTharimmune files to sell 2.46M shares of common stock for holdersAugust 26, 2025 | msn.comTharimmune Inc trading halted, volatility trading pauseAugust 26, 2025 | msn.comTharimmune Shares Drop After Securities Purchase AgreementAugust 26, 2025 | marketwatch.comWhy Tharimmune (THAR) Stock Exploded This WeekAugust 23, 2025 | msn.comWhy Is Tharimmune Stock (THAR) Blowing Up?August 22, 2025 | msn.comWhy Is Tharimmune Stock (THAR) Exploding Higher?August 21, 2025 | tipranks.comTharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential ...August 20, 2025 | newsobserver.comNTharimmune reports pharmacokinetic simulation results for TH104August 20, 2025 | msn.comTharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing TreatmentsAugust 20, 2025 | accessnewswire.comATharimmune secures key global patents for TH-104August 13, 2025 | msn.comTharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against ...August 13, 2025 | charlotteobserver.comCTharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized FentanylAugust 13, 2025 | accessnewswire.comATharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral ...August 6, 2025 | freep.comFNancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of DirectorsAugust 5, 2025 | accessnewswire.comATharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody DeliveryAugust 4, 2025 | accessnewswire.comATharimmune Completes Private Placement AgreementAugust 1, 2025 | msn.comTharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and WarrantsJuly 23, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEON, THAR, DYAI, and RNTX Company DescriptionsAEON Biopharma NASDAQ:AEON$0.77 -0.04 (-5.22%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$0.77 +0.00 (+0.43%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Dyadic International NASDAQ:DYAI$0.96 -0.02 (-2.28%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$0.94 -0.01 (-1.24%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Rein Therapeutics NASDAQ:RNTX$1.37 +0.11 (+8.73%) As of 09/4/2025 03:51 PM EasternRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.Tharimmune NASDAQ:THAR$3.99 -0.78 (-16.35%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$4.15 +0.16 (+3.91%) As of 05:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
